Geroa Diagnostics is a clinical-stage in vitro diagnostics company developing a novel salivary diagnostic biomarker for Alzheimer’s Disease (AD). Our patent-protected biomarker addresses the key unmet needs in AD diagnostics including being a low cost, non-invasive, technique that is well-suited to disseminated community-based testing.
Watch our video
MEET THE TEAM
Juan Carlos del Castillo
Co-Founder and CFO
Juan Carlos is an entrepreneurial executive with 22 years of broad experience managing and leading both large research centers and innovative private companies in virtually all fields of biotechnology.
Since leaving 1999 the management of the National Center of Biotechnology of Spain, Juan Carlos has been managing director of Grupo Genetrix (till August 2015), a reference holding in the Spanish Biotechnology.
Genetrix has contributed to the development of the biotechnology in Spain, incorporating some of its most prominent companies. Two of them are listed on the Frankfurt and Brussels stock exchanges.
Gorka Orive, PhD
Co-Founder and CSO
Gorka holds a Bachelor degree in Pharmacy and his PhD from the University of the Basque Country (Vitoria, Spain). He is Associate Professor in Pharmacy at the University of the Basque Country.
He is advisor at Singapore Eye Research Institute (Singapore) and active scientist of the Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN).
He has 300 international scientific publications, 70 publications in national journals, 35 book chapters and 4 books as editor. He has currently a H-index of 65 and more than 16000 citations.
He has won several excellence and scientific awards and has been advisor for different companies.
Eva Carro, PhD
Co-Founder and External Scientific Advisor
Lead of the Neurodegenerative Diseases group at the Hospital 12 de Octubre Research Institute (imas12) and Research Networking Center in Neurodegenerative Diseases (CIBERNED). PhD in Biology in 1998 at the Santiago de Compostela University, Spain. She completed several postdoctoral stays including the Instituto Cajal-CSIC, Madrid, Spain, the Reed Neurology Center, UCLA, LA, USA and the Institute Pasteur, Paris, France.
In 2005 she was moved to Hospital 12 de Octubre working on her own line of research in the field of Alzheimer’s disease and other neurodegenerative diseases. In 2019 she was appointed Neuroscience and Mental Health Coordinator at the Hospital 12 de Octubre Research Institute.
She brings more than 15 years of experience in neurology research. Her scientific activity is focused at studying pathophysiological mechanisms of neurodegenerative diseases, mainly Alzheimer’s disease and associated dementias. She has published more than 120 refereed articles, 8 patents, and possesses an h-index of 37.
Robert Jenkins, PhD MBA
Bob has 25 years of global experience in the healthcare industry including six years in global business development for a leading in vitro diagnostics company, seven years in business development and head of US operations for a genomics start up as well as several years in strategy consulting.